
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
The American Journal of Managed Care
over 24 years ago
A New Era of Leadershipover 24 years ago
The Potential of Pill Splitting to Achieve Cost Savingsover 24 years ago
Reducing Cesarean Delivery Rates in Managed Care Organizations





